Finanical Reports

Explore the landscape of Finanical Reports in China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data and insights on Finanical Reports to help you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

IASO Bio Partners with Shenzhen Longuide to Deploy LNP Technology Beyond Oncology – Broadening the Cell Therapy Innovator's Advanced Therapeutics Portfolio
CompanyDeals

IASO Bio Partners with Shenzhen Longuide to Deploy LNP Technology Beyond Oncology – Broadening the Cell Therapy Innovator’s Advanced Therapeutics Portfolio

IASO Biotherapeutics (IASO Bio), a Chinese cell therapy innovator, announced a strategic partnership with Shenzhen Longuide Biopharma Corporation (Longuide), under which IASO Bio will leverage Longuide's lipid nanoparticle (LNP) technology…

China's NHC Issues Working Procedures for Rare Disease Catalogue (2026 Edition) – Expanded Inclusion Criteria and Faster Update Cycle Reshape Drug Access Landscape

China’s NHC Issues Working Procedures for Rare Disease Catalogue (2026 Edition) – Expanded Inclusion Criteria and Faster Update Cycle Reshape Drug Access Landscape

Nxera Pharma Licenses Oral EP4 Agonist NXE0033744 to AbbVie in up to USD 1.47 Billion IBD Deal – Validating the NxWave Discovery Platform

Nxera Pharma Licenses Oral EP4 Agonist NXE0033744 to AbbVie in up to USD 1.47 Billion IBD Deal – Validating the NxWave Discovery Platform

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Novo Nordisk Raises Full‑Year Guidance on Oral Wegovy Momentum – Q3 Revenue Grows 6% as China Sales Weaken
Company

Novo Nordisk Raises Full‑Year Guidance on Oral Wegovy Momentum – Q3 Revenue Grows 6% as China Sales Weaken

Pfizer Raises Full‑Year 2026 Guidance as Q3 Revenue Holds Flat at $16.6 Billion – Launched and Acquired Products Surge 32%, Cecile Guegan Named CFO
Company

Pfizer Raises Full‑Year 2026 Guidance as Q3 Revenue Holds Flat at $16.6 Billion – Launched and Acquired Products Surge 32%, Cecile Guegan Named CFO

Bayer Q3 2026 Sales Reach €10.053 Billion as Pharmaceuticals Division Hits Growth Turning Point – Nubeqa and Kerendia Lead the Rebound
Company

Bayer Q3 2026 Sales Reach €10.053 Billion as Pharmaceuticals Division Hits Growth Turning Point – Nubeqa and Kerendia Lead the Rebound

Eli Lilly Q3 Revenue Soars 39% to USD 24.4 Billion as Mounjaro Sales Jump 65% and China Revenue Climbs 69%; Full‑Year Guidance Raised to USD 91–92 Billion
Company

Eli Lilly Q3 Revenue Soars 39% to USD 24.4 Billion as Mounjaro Sales Jump 65% and China Revenue Climbs 69%; Full‑Year Guidance Raised to USD 91–92 Billion

BMS Q3 Revenue Rises 7% to USD 13.1 Billion as Eliquis Surges 25% and Growth Portfolio Climbs 12%; Full‑Year Outlook Raised
Company

BMS Q3 Revenue Rises 7% to USD 13.1 Billion as Eliquis Surges 25% and Growth Portfolio Climbs 12%; Full‑Year Outlook Raised

MSD Q3 Revenue Rises 5% to USD 18.1 Billion as Keytruda Anchors Growth and China Pharmaceutical Sales Recover 14%
Company

MSD Q3 Revenue Rises 5% to USD 18.1 Billion as Keytruda Anchors Growth and China Pharmaceutical Sales Recover 14%

Gilead Q3 Product Sales Jump 13% to USD 8.3 Billion as HIV Franchise Grows 18%; Full‑Year Guidance Raised to USD 31.0–31.3 Billion
Company

Gilead Q3 Product Sales Jump 13% to USD 8.3 Billion as HIV Franchise Grows 18%; Full‑Year Guidance Raised to USD 31.0–31.3 Billion

AbbVie Q3 Revenue Climbs 10.3% to USD 17.4 Billion as Skyrizi and Rinvoq Drive Immunology Growth; Full‑Year EPS Guidance Raised
Company

AbbVie Q3 Revenue Climbs 10.3% to USD 17.4 Billion as Skyrizi and Rinvoq Drive Immunology Growth; Full‑Year EPS Guidance Raised

Show More